Tumor necrosis factor-alpha, transforming growth factor-beta, degree of lower urinary tract symptoms as predictors of erectile dysfunction in benign prostatic hyperplasia patients

doi:10.1016/j.ajur.2023.07.003

Asian Journal of Urology, 2024, 11 (2): 280-285 doi: 10.1016/j.ajur.2023.07.003

Regular Papers: Original Articles

Tumor necrosis factor-alpha, transforming growth factor-beta, degree of lower urinary tract symptoms as predictors of erectile dysfunction in benign prostatic hyperplasia patients

Gede W.K. Duarsa^a,*(

),Yeremia G. Kusumah^b,Ronald Sugianto^c,Pande M.W. Tirtayasa^d,Tjokorda G.B. Mahadewa^e

^aDepartment of Urology, Faculty of Medicine, Universitas Udayana, Prof. Dr. I.G.N.G Ngoerah General Hospital, Bali, Indonesia
^bDepartment of General Surgery, Faculty of Medicine, Universitas Udayana, Prof. Dr. I.G.N.G Ngoerah General Hospital, Bali, Indonesia
^cMedical Doctor Study Program, Faculty of Medicine, Universitas Udayana, Bali, Indonesia
^dDepartment of Urology, Faculty of Medicine, Universitas Udayana, Universitas Udayana Teaching Hospital, Bali, Indonesia
^eDepartment of Neurosurgery, Faculty of Medicine, Universitas Udayana, Prof. Dr. I.G.N.G Ngoerah General Hospital, Bali, Indonesia

Abstract
Related Citation (15)

Download:

HTML

PDF (896KB)
Export: BibTeX | EndNote (RIS)

Abstract

Objective: Erectile dysfunction (ED) is a condition of insufficient penile erection, consistently or recurrently, for sexual activity. Tumor necrosis factor-alpha (TNF-α) induces transforming growth factor-beta (TGF-β), which causes the transition of epithelial cells into mesenchymal cells that affect ED. This study aimed to evaluate the roles of TNF-α, TGF-β, degree of lower urinary tract symptoms, and prostatic volume for the presence of ED in benign prostatic hyperplasia (BPH) patients.

Methods: Our study performed an analytic observational retrospective cohort study using secondary data from four hospitals in Bali, Indonesia, including medical records and other administrative data. The sample was BPH patients with several history qualifications.

Results: Our sample was 83 respondents, ranging from 50 years to 80 years, 61 respondents with ED and 22 with non-ED. The International Prostate Symptom Score showed a significant result, which indicates that ED is more common in patients with higher International Prostate Symptom Score (p=0.002). Moreover, the TNF-α of ≥43.9 pg/mg and TGF-β of ≥175.8 pg/mL were significantly associated with the presence of ED in BPH patients (p<0.0001). Despite these results, prostate volume is not significant with ED (p=0.947).

Conclusion: TNF-α, TGF-β, and lower urinary tract symptoms severity can predict the occurrence of ED in BPH, while prostatic volume was not significant.

Key words： Prostate enlargement Biomarker Erectile dysfunction Risk factor

Received: 13 March 2023 Available online: 20 April 2024

Corresponding Authors: * E-mail address: gwkurology@gmail.com (G.W.K. Duarsa).

	Service
	E-mail this article
	Add to citation manager
	E-mail Alert
	Articles by authors
	Gede W.K. Duarsa
	Yeremia G. Kusumah
	Ronald Sugianto
	Pande M.W. Tirtayasa
	Tjokorda G.B. Mahadewa

TRENDMD:

Cite this article:

Gede W.K. Duarsa,Yeremia G. Kusumah,Ronald Sugianto, et al. Tumor necrosis factor-alpha, transforming growth factor-beta, degree of lower urinary tract symptoms as predictors of erectile dysfunction in benign prostatic hyperplasia patients[J]. Asian Journal of Urology, 2024, 11(2): 280-285.

URL:

http://www.ajurology.com/EN/10.1016/j.ajur.2023.07.003 OR http://www.ajurology.com/EN/Y2024/V11/I2/280

Characteristics of respondents.

Bivariate analysis of variables with risk factors for ED in benign prostatic hyperplasia patients.

Receiver operating characteristic curves. (A) Tumor necrosis factor-alpha; (B) Transforming growth factor-beta.

AUC value, sensitivity, and specificity of TNF-α and TGF-β.

Results of multivariate analysis.

[1]	McCabe MP, Althof SE. A systematic review of the psychosocial outcomes associated with erectile dysfunction: does the impact of erectile dysfunction extend beyond a man’s inability to have sex? J Sex Med 2014; 11:347e63. doi: 10.1111/jsm.12374
[2]	Corona G, Lee DM, Forti G, O’Connor DB, Maggi M, O’Neill TW, et al. Age-related changes in general and sexual health in middle-aged and older men: results from the European male ageing study (EMAS). J Sex Med 2010; 7: 1362e80.
[3]	Lu SH, Chen CS. Natural history and epidemiology of benign prostatic hyperplasia. Formos J Surg 2014; 47:207e10. doi: 10.1016/j.fjs.2014.10.001
[4]	Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44:637e49. doi: 10.1016/j.eururo.2003.08.015 pmid: 14644114
[5]	Afdal A, Darwin E, Yanwirasti Y, Hamid R. The expression of transforming growth factor beta-1 and interleukin-6 on human prostate: prostate hyperplasia and prostate cancer. Open Access Maced J Med Sci 2019; 7:1905e10. doi: 10.3889/oamjms.2019.548 pmid: 31406527
[6]	Wang M, Liu X, Chen Z, Chen H, Tan Y. Metformin suppressed tumor necrosis factor-a-induced epithelial-mesenchymal transition in prostate cancer by inactivating the NF-kB signaling pathway. Transl Cancer Res 2020; 9:6086e95. doi: 10.21037/tcr-20-1186 pmid: 35117220
[7]	Sambel M, Kilic M, Demirbas M, Onen E, Oner S, Erdogan A, et al. Relationship between erectile dysfunction and the neutrophil to lymphocyte and platelet to lymphocyte ratios. Int J Impot Res 2018; 30:27e35. doi: 10.1038/s41443-017-0007-1 pmid: 29196693
[8]	Madersbacher S, Sampson N, Culig Z. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a mini-review. Gerontology 2019; 65:458e64. doi: 10.1159/000496289 pmid: 30943489
[9]	Yafi FA, Jenkins L, Albersen M, Corona G, Isidori AM, Goldfarb S, et al. Erectile dysfunction. Nat Rev Dis Prim 2016; 2:16003. https://doi.org/10.1038/nrdp.2016.3.
[10]	De Nunzio C, Roehrborn CG, Andersson KE, McVary KT. Erectile dysfunction and lower urinary tract symptoms. Eur Urol Focus 2017; 3:352e63. doi: S2405-4569(17)30260-2 pmid: 29191671
[11]	Seftel AD, de la Rosette J, Birt J, Porter V, Zarotsky V, Viktrup L. Coexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological data: coexisting lower urinary tract symptoms and erectile dysfunction. Int J Clin Pract 2013; 67:32e45. doi: 10.1111/ijcp.12044 pmid: 23082930
[12]	Gacci M, Andersson KE, Chapple C, Maggi M, Mirone V, Oelke M, et al. Latest evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2016; 70:124e33. doi: 10.1016/j.eururo.2015.12.048
[13]	Wang L, Wang T, Liu J, Wang J. Correlation analysis of erectile dysfunction with lower urinary tract symptoms (LUTS) degree and clinical features in LUTS patients. Iran J Public Health 2018; 47:658e65. pmid: 29922607
[14]	Duarsa GWK, Oka AAG, Maliawan S, Soebadi DM, Astawa P, Bakta M, et al. Elevated tumor necrosis factor-a and transforming growth factor-b in prostatic tissue are risk factors for lower urinary tract symptoms after transurethral resection of the prostate in benign prostatic hyperplasia patients with urinary retention. Open Urol Nephrol J 2018; 11:46e53. doi: 10.2174/1874303X01811010046
[15]	Carneiro FS, Webb RC, Tostes RC. Emerging role for TNF-a in erectile dysfunction. J Sex Med 2010; 7:3823e34. doi: 10.1111/j.1743-6109.2010.01762.x
[16]	Shah A, Shah AA, Nandakumar K, Lobo R. Mechanistic targets for BPH and prostate cancerda review. Rev EnvironHealth 2020; 36: 261e70.
[17]	De Nunzio C, Presicce F, Tubaro A. Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nat Rev Urol 2016; 13:613e26. doi: 10.1038/nrurol.2016.168 pmid: 27686153
[18]	Partin AW, Kavoussi LR, Peters CA, Novick AC. Campbell-walsh urology. 11th ed. Philadelphia, USA: Elsevier Inc.; 2015. p.546.
[19]	Agrawal C, Chalise P, Bhandari B. Correlation of prostate volume with international prostate symptom score and quality of life in men with benign prostatic hyperplasia. Nepal Med Coll J 2008; 10:104e7. pmid: 18828432
[20]	Hossain A, Alam A, Habib A, Rashid M, Rahman H, Islam A, et al. Comparison between prostate volume and intravesical prostatic protrusion in detecting bladder outlet obstruction due to benign prostatic hyperplasia. Bangladesh Med Res Counc Bull 2012; 38:14e7. pmid: 22545345
[21]	Bassey IAE, Isiwele EM. Correlation of international prostate symptom score with prostate volume and quality of life in a screened population of university workers. Int J Contemp Med 2018; 5. https://www.ijcmr.com/uploads/7/7/4/6/77464738/ijcmr_1843_v1.pdf.